NTRK1 NTRK1 FUSIONS Detail (hg19) (NTRK1)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr1:156,844,175-156,851,434 |
| hg38 | chr1:156,874,383-156,881,642 View the variant detail on this assembly version. |
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
| Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung adenocarcinoma | Crizotinib,Larotrectinib,Lestaurtinib | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 24162815 | Detail |
| lung non-small cell carcinoma | Entrectinib | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 26565381 | Detail |
| cancer | Entrectinib | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 28183697 | Detail |
| cancer | Larotrectinib | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 26603524 | Detail |
| sarcoma | Larotrectinib | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 26216294 | Detail |
| cancer | Larotrectinib | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 29466156 | Detail |
| cancer | Larotrectinib | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 29606586 | Detail |
| colorectal cancer | Larotrectinib | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 26716414 | Detail |
DisGeNET
[No Data.]
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| Two patients were found to harbor gene fusions maintaining the kinase domain of NTRK1 (3' partner), ... | CIViC Evidence | Detail |
| 1378 cases of NSCLC were screened. One patient (frequency 0.1%) with a NTRK1 gene rearrangement (SQS... | CIViC Evidence | Detail |
| in two phase I studies in patients with advanced or metastatic solid tumors, including patients with... | CIViC Evidence | Detail |
| Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, w... | CIViC Evidence | Detail |
| LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the ... | CIViC Evidence | Detail |
| This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tum... | CIViC Evidence | Detail |
| In a Phase 1/2 study involving 15 pediatric patients with infantile fibrosarcoma or soft tissue sarc... | CIViC Evidence | Detail |
| NTRK1 fusions (one LMNA-NTRK1 and two TPM3-NTRK1) were identified in 2% of Korean colorectal cancer ... | CIViC Evidence | Detail |
- Gene
- NTRK1
- Genome
- hg19
- Position
- chr1:156,844,175-156,851,434
- Variant Type
- fusion
- Variant (CIViC) (CIViC Variant)
- NTRK1 FUSIONS
- Transcript 1 (CIViC Variant)
- ENST00000524377.1
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/419
Genome browser